VANCOUVER, May 28, 2019 /CNW/ - Sirona Biochem Corp.
(TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce
safety testing on its lead glycoprotein compound in the
anti-wrinkle program yielded excellent results and the company will
immediately move to the next steps of development. This project was
generously supported by BPI France and the region Haute
Normandie.
The comprehensive safety analysis was performed by CEHTRA
(www.cehtra.com), cosmetic toxicology specialists in Paris, France. Key in vitro measures
and in silico analyses of safety were evaluated, including skin
irritation, skin sensitization, ocular tolerability, phototoxicity,
genotoxicity and carcinogenicity. It was concluded that there is no
evidence of these issues in the testing. Also, based on in silico
analysis, no systemic toxicity is expected.
"These are very encouraging results for our anti-wrinkle
program. Sirona's scientists at our French subsidiary, TFChem, will
be focusing their efforts on the next set of tests and a detailed
project plan to make this a priority. There is still work to be
done in the lab, but we have nicely de-risked the project by
conducting these safety assays", reports Dr. Howard Verrico, CEO of Sirona Biochem.
Next steps in the program will include additional in vitro
assays for a second review by CEHTRA to determine dosing. This will
be followed by synthetic process refinements, synthesis of a batch
for formulation, skin permeation study and clinical safety
evaluation.
Loss of elasticity and degradation of fat tissue are two markers
seen in aging skin, leading to the appearance of lines and
wrinkles. Compounds that increase the number and volume of
adipocytes (fat cells) can act as plumping, volumizing, and
densifying skin agents, thereby reducing the visibility of wrinkle
and potentially providing a more youthful look. Novel solutions are
actively being sought out by the dermatology industry to address
this.
The global anti-aging market is forecast to reach up to
US$271.0 Billion by
2024.1 The anti-wrinkle product category held the
largest share in the anti-aging market, with 59.3% contribution in
2017.2
The anti-wrinkle potential of LIP-01 is as a non-invasive
treatment for fine wrinkles by a mechanism very different from
dermal fillers and Botox®. Botox®3 is generally limited
to use on the upper third of the face, specifically the frown lines
between the eyebrows. Botox® also requires administration by a
properly trained professional.
"Less of our team's resources are needed on the skin lightening
project as its development is now mainly focused on manufacturing.
We are excited to have the opportunity to continue expanding the
powerful technology platform developed by our Chief Scientific
Officer Dr. Geraldine Deliencourt
and her team. This anti-wrinkle compound has fascinating properties
in cells and we anticipate moving it along quickly. If clinically
successful, LIP-01 could exceed Botox in market potential," Dr.
Verrico concluded.
_______________________________
|
|
|
1
|
www.marketwatch.com/press-release/anti-aging-market-is-determined-to-grow-us-2710-billion-by-2024-2019-02-08
|
|
|
2
|
www.psmarketresearch.com/market-analysis/anti-aging-market
|
|
|
3
|
BOTOX COSMETIC®
is a registered trademark of Allergan Inc.
|
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French
national scientific awards and European Union and French government
grants. For more information, please
visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this press release.
---------------------------------------------
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.